# Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia

> **NIH NIH R37** · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2022 · $395,738

## Abstract

PROJECT SUMMARY/ABSTRACT
 MLL-rearranged (MLL-r) leukemias account for 5-10% of human acute leukemia and is associated with
poor prognosis. The unmet clinical needs and the lack of an effective targeted therapy to the MLL-r
leukemias emphasize the need for novel regimens. Recent cancer epigenetics studies discovered a central
role for the histone H3 lysine 79 (H3K79) methyltransferase DOT1L in MLL-r leukemogenesis. Important
clinical responses have been noted with DOT1L inhibitor treatment as a single agent, however, it is expected
that combination treatments will be necessary.
 Our preliminary studies based on a DOT1L-inhibitor sensitization screen have identified an essential role
of the PHF20/KAT8 histone acetyltransferase complex, in supporting the expression of DOT1L-driven
oncogenes. The objective of this application is to determine the critical epigenetic mechanisms that
collaborate with DOT1L to maintain oncogene expression in MLL-r leukemia. Our central hypothesis is
that PHF20 mediates KAT8 recruitment to maintain the locus-specific histone acetylation and transcription
of the DOT1L-driven leukemic program. We will investigate the efficacy of DOT1L and PHF20/KAT8
combination therapies (Aim 1), dissect the PHF20/KAT8 chromatin targeting mechanisms (Aim 2), and
validate a novel high-density CRISPR protein scan technology for de novo discovery of the functional
elements in DOT1L/PHF20/KAT8 (Aim 3).
 This study is innovative because (1) it introduces a novel concept of simultaneously targeting multiple
components of an epigenetic feed-forward loop to efficiently suppress the cancer programs, and (2) it
establishes a brand new genetic screen approach for a sub-protein level functional domain discovery. The
impact of this research will be of significance because (1) it immediately provides novel therapeutic
opportunities against the difficult-to-treat MLL-r leukemias, and (2) it will help identify novel functional
elements in epigenetic regulators for future pharmaceutical targeting.

## Key facts

- **NIH application ID:** 10306337
- **Project number:** 5R37CA233691-04
- **Recipient organization:** BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- **Principal Investigator:** Chun-Wei David Chen
- **Activity code:** R37 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $395,738
- **Award type:** 5
- **Project period:** 2018-12-03 → 2023-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10306337

## Citation

> US National Institutes of Health, RePORTER application 10306337, Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia (5R37CA233691-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10306337. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*